Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last 12.55 NOK
Change Today -0.55 / -4.20%
Volume 33.6K
NATTO On Other Exchanges
Symbol
Exchange
Berlin
As of 10:25 AM 05/29/15 All times are local (Market data is delayed by at least 15 minutes).

nattopharma asa (NATTO) Snapshot

Open
13.00 NOK
Previous Close
13.10 NOK
Day High
13.00 NOK
Day Low
11.50 NOK
52 Week High
07/2/14 - 22.09 NOK
52 Week Low
10/13/14 - 9.33 NOK
Market Cap
215.1M
Average Volume 10 Days
28.5K
EPS TTM
-1.54 NOK
Shares Outstanding
17.1M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for NATTOPHARMA ASA (NATTO)

Related News

No related news articles were found.

nattopharma asa (NATTO) Related Businessweek News

No Related Businessweek News Found

nattopharma asa (NATTO) Details

NattoPharma ASA produces nutrition supplements. It offers MenaQ7 that provides natural vitamin K2 (Menaquinone-7) as a fermentation extract for use in dietary supplements, and functional and fortified foods. The company sells its products through retail pharmacies. NattoPharma ASA was founded in 2004 and is based in Høvik, Norway.

10 Employees
Last Reported Date: 04/13/15
Founded in 2004

nattopharma asa (NATTO) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

nattopharma asa (NATTO) Key Developments

NattoPharma ASA, Q1 2015 Earnings Call, May 29, 2015

NattoPharma ASA, Q1 2015 Earnings Call, May 29, 2015

NattoPharma ASA Names Rudi De Man as VP Sales & Business Development

Rudi De Man has been appointed Vice President of Sales and Business Development of NattoPharma ASA, responsible for Europe and Asia. Prior to joining NattoPharma, De Man held sales leadership and business development roles where he was directly responsible for driving record growth in the FMC Health and Nutrition division. Reporting to NattoPharma COO Daniel H. Rosenbaum, De Man will be responsible for driving sales in Europe and Asia, while growing awareness of MenaQ7. He will provide technical expertise to regional partners and key accounts, identifying and developing opportunities to leverage existing proprietary MenaQ7 Vitamin K2 science and technology, and directly contributing to the company's global strategy and growth intiatives.

NattoPharma ASA's MenaQ7 PURE Obtains Novel Food Approval from EFSA

NattoPharma ASA has received written information from the Policy officer in the European Commission, DG Health and Food Safety, communicating that MenaQ7 PURE has received Novel Food approval by EFSA. As per the date of the NattoPharma Prospectus, April 10th 2015, such approval was not received. The MenaQ7 PURE product is a high quality product with efficient production costs. In combination with high quality this product is a good option for customers requiring low cost products, either by introducing MenaQ7 into existing products or by developing new product lines. NattoPharma considers that the potential for growth and increased revenues are within the synthetic products market within these segments, requiring huge volumes of MenaQ7 material.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NATTO:NO 12.55 NOK -0.55

NATTO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for NATTO.
View Industry Companies
 

Industry Analysis

NATTO

Industry Average

Valuation NATTO Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 4.5x
Price/Book 2.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales 7.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NATTOPHARMA ASA, please visit www.nattopharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.